Answer
Carbidopa in Co-Careldopa inhibits peripheral dopa decarboxylase, preventing levodopa from being converted to dopamine in the peripheral circulation so that a higher proportion reaches the brain.
Sources for this answer
- Co-Careldopa 12.5mg/50 mgStrides Pharma UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 1Document updated
Sources checked